This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Ackman's J.C. Penney Exit Won't Kill Activist Investing

Stocks in this article: JCP MSFT HMA SNE YHOO

NEW YORK ( TheStreet) -- Bill Ackman's exit from J.C. Penney's (JCP - Get Report) board of directors isn't a death knell for activist investing.

Ackman's departure from J.C. Penney comes after his hand-picked CEO Ron Johnson failed to turn around the struggling retail giant, and the hedge funder waged a losing war over the company's management and strategy. Many now wonder whether J.C. Penney can make it past the holidays, after spending billions on a failed store revamp that drained the company's cash coffers.

J.C. Penney elected retail industry veteran Ronald W. Tysoe, the former vice chairman of what is now Macy's (M), to the company's board on Tuesday, a move Ackman said he supports.

The hedge funder's retreat at J.C. Penney comes as his nemesis, Daniel Loeb of Third Point Capital Management, was forced by Hollywood icon George Clooney to backtrack from highly critical comments he made to Sony's (SNE - Get Report) management. Loeb owns about $1 billion in Sony shares and seeks to spin off the company's movie studio business in an attempt to revive the struggling electronics giant.

Carl C. Icahn, the dean of modern day activist investing, meanwhile, faces the imminent prospect of failing to win over Dell (DELL) shareholders on a competing bid to what could be one of the biggest leveraged buyouts in history.

Ackman, Loeb and Icahn are all intimately connected to a drama at Herbalife (HLF). Ackman has bet $1 billion that the company is little more than a Ponzi scheme. Loeb and Icahn have publicly taken the other side of Ackman's trade and have, so far, made millions of dollars in profit. "New HLF product: The Herbalife Enema administered by Uncle Carl," Loeb wrote on his Bloomberg profile in July.

Clearly, a crass breed of barbarians is storming the gates of Corporate America. What board would let them in?

The answer is that while Ackman, Loeb and Icahn may be pushing the limits of good judgment, they will continue to have a significant influence on markets.

Ackman, after all, remains an independent director on Canadian Pacific's (CP) board. Meanwhile, the hedge funder has recently made a play at chemicals giant Air Products (APD). Loeb can count a turnaround at Yahoo! (YHOO - Get Report) under new CEO Marissa Mayer as a major recent activist success.

Loeb, at times, resorted to crude tactics such as publicly shaming Yahoo!'s former CEO Scott Thompson. With hindsight, the company's shareholders are likely to view such actions as necessary.

Carl Icahn helped to pull Chesapeake Energy (CHK ) from the brink of bankruptcy after building an investor consortium on the embattled oil and gas driller's board. Analysts see Icahn's influence as helping impart Chesapeake's management change and its execution on needed asset sales and capital expenditure reductions.

Lessons Learned

Still, Ackman and Loeb are likely to consider recent setbacks at J.C. Penney and Sony as a learning experience. If either hedge fund manager considers changing their tactics, there are others to follow who play a less-heralded but similarly influential role on investments.

Jeffrey Ubben of ValueAct Capital Management, while generally media shy, may be the activist to watch this year. Quietly, Ubben and ValueAct have won board seats and supported drastic changes at firms such as Adobe (ADBE ) and Valeant Pharmaceuticals (VRX) that are paying off for shareholders.

ValueAct may be on the verge of its most impressive activist investments yet after taking a large position in Microsoft (MSFT - Get Report) shares earlier in 2013. While Microsoft is the dominant player in PC-software, its earnings outlook has become clouded by a string of failed attempts to enter the smartphone and tablet markets.

Ubben told TheStreet in 2012 that he liked to work with management in so-called activist investments and has recently pushed for firms to consider mergers and acquisitions. Microsoft may presently be in need of a transformative acquisition and the company is consistently speculated as an acquirer.

In the health care sector, Larry Robbins of Glenview Management operates in a similarly understated manner, even if the hedge funder has assembled a multi-billion dollar bet on the consolidating health care sector. On Monday, Glenview won a shareholder vote to take full control of Health Management's Associates (HMA ) board of directors as they seek a higher share price to Community Health Management's (CYH ) near $4 billion bid for the company.

Like Ubben, Robbins can be described as an "activist" investor; however, he prefers the notion of being a "suggestivist" who works with management in most cases. Shareholder votes such as the one conducted at Health Management on Monday indicate Robbins' style has a high degree of credibility with investors in the health care sector.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,387.21 -291.49 -1.65%
S&P 500 2,029.55 -27.54 -1.34%
NASDAQ 4,681.4970 -90.2660 -1.89%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs